Encephalitis in Patients with COVID-19: A Systematic Evidence-Based Analysis
Open Access
- 18 August 2022
- Vol. 11 (16), 2575
- https://doi.org/10.3390/cells11162575
Abstract
Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) predominantly infects the respiratory system, several investigations have shown the involvement of the central nervous system (CNS) along the course of the illness, with encephalitis being one of the symptoms. The objective of this systematic review was to evaluate the characteristics (clinical, neuro-radiological aspects, and laboratory features) and outcomes of encephalitis in COVID-19 patients. PubMed, Scopus, and Google Scholar databases were searched from 1 December 2019 until 21 July 2022 to identify case reports and case series published on COVID-19 associated with encephalitis. The quality of the included studies was assessed by the Joanna Briggs Institute critical appraisal checklists. This systematic review included 79 studies, including 91 COVID-19 patients (52.7% male) experiencing encephalitis, where 85.6% were adults (49.3 ± 20.2 years), and 14.4% were children (11.2 ± 7.6 years). RT-PCR was used to confirm 92.2% of the COVID-19 patients. Encephalitis-related symptoms were present in 78.0% of COVID-19 patients at the time of diagnosis. In these encephalitis patients, seizure (29.5%), confusion (23.2%), headache (20.5%), disorientation (15.2%), and altered mental status (11.6%) were the most frequently reported neurologic manifestations. Looking at the MRI, EEG, and CSF findings, 77.6%, 75.5%, and 64.1% of the patients represented abnormal results. SARS-CoV-2-associated or -mediated encephalitis were the most common type observed (59.3%), followed by autoimmune encephalitis (18.7%). Among the included patients, 66.7% were discharged (37.8% improved and 28.9% fully recovered), whereas 20.0% of the reported COVID-19-positive encephalitis patients died. Based on the quality assessment, 87.4% of the studies were of high quality. Although in COVID-19, encephalitis is not a typical phenomenon, SARS-CoV-2 seems like a neuropathogen affecting the brain even when there are no signs of respiratory illness, causing a high rate of disability and fatality.This publication has 117 references indexed in Scilit:
- A first case of meningitis/encephalitis associated with SARS-Coronavirus-2International Journal of Infectious Diseases, 2020
- Nervous system involvement after infection with COVID-19 and other coronavirusesBrain, Behavior, and Immunity, 2020
- Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2Science, 2020
- The neuroinvasive potential of SARS‐CoV2 may play a role in the respiratory failure of COVID‐19 patientsJournal of Medical Virology, 2020
- 0.9% saline versus Plasma-Lyte as initial fluid in children with diabetic ketoacidosis (SPinK trial): a double-blind randomized controlled trialCritical Care, 2020
- The value of cerebrospinal fluid α‐synuclein and the tau/α‐synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathologyEuropean Journal of Neurology, 2019
- Acute encephalitis – diagnosis and managementClinical Medicine, 2018
- Diagnosis and management of acute encephalitisNeurology Clinical Practice, 2014
- Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesisThe Journal of Pathology, 2004
- Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzymeFEBS Letters, 2002